NKGN VS RMTI Stock Comparison

PerformanceVolatilityAnalyst Price TargetsTechnicalsEarningsProfit
PerformanceVolatilityAnalyst Price TargetsTechnicalsEarningsProfit

Performance

NKGN
10/100

NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

RMTI
100/100

RMTI returned 42.03% in the last 12 months. Based on SPY's performance of -13.07%, its performance is above average giving it a score of 100 of 100.

Volatility

NKGN
10/100

NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.

RMTI
44/100

RMTI has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Analyst Price Targets

NKGN

"Analyst Price Targets" not found for NKGN

RMTI
58/100

3 analysts offer 12-month price targets for RMTI. Together, they have an average target of 11, the most optimistic target put RMTI at 11 within 12-months and the most pessimistic has RMTI at 11.

Technicals

NKGN

"Technicals" not found for NKGN

RMTI
57/100

RMTI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

Earnings

NKGN

"Earnings" not found for NKGN

RMTI
10/100

RMTI has missed earnings 7 times in the last 20 quarters.

Profit

NKGN

"Profit" not found for NKGN

RMTI
10/100

Out of the last 20 quarters, RMTI has had 0 profitable quarters and has increased their profits year over year on 0 of them.

All score calculations are broken down here to help you make more informed investing decisions

NKGen Biotech, Inc. Common Stock Summary

Nasdaq / NKGN
Healthcare
Biotechnology
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.

Rockwell Medical, Inc. (DE) Common Stock Summary

Nasdaq / RMTI
Healthcare
Drug Manufacturers - Specialty & Generic
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.